Skip to main content

Advertisement

Table 2 Summary of adverse drug reactions

From: Exploratory study of tolerability and immunological effect of a short up-dosing immunotherapy phase with a standardised allergen extract derived from pollen of Olea europaea

  e n (%)
IMP-related adverse events 95 34 (36.6)
Severity
  Mild 95 34 (36.6)
  Moderate 0 0
  Severe 0 0
Change in treatment schedule
  None 93 33 (35.5)
  Temporarily interrupted 2 1 (1.1)
  Discontinued 0 0
  Prior to first intake 0 0
Classification according to EAACI guideline
  LR 85 32 (34.4)
  SR 9 4 (4.3)
  Grade 0/Nonspecific 1 1 (1.1)
Dose
  300 SQ+ 16 13 (14.0)
  600 SQ+ 11 11 (11.8)
  3,000 SQ+ 24 22 (23.7)
  6,000 SQ+ 17 17 (18.3)
  15,000 SQ+ 26 15 (16.1)
  Dose unknown 1 1 (1.1)
  1. ADR adverse drug reaction, e number of events, EAACI European Academy of Allergy and Clinical Immunology, n (%) number and percentage of subjects, LR local reactions, SQ+ standardized quality units, SR systemic reactions